| abstract |
Disclosed are 2,6-quinolinyl derivatives of formula I, their enantiomers, diastereoisomers or pharmaceutical salts thereof, wherein R1 is hydrogen, hydroxyl, methoxy or alkyl; R2 is hydrogen or halogen; n is 0 to 5; R3 is hydrogen or halogen; n' is 0 to 4. Of particular importance are the compounds methyl-(2S)-2-[(3,5-dichloroisonicotinoyI)amino]-3-[2-(2,6-dichiorophenyl)-6-quinolinyl]propanoate and (2S)-2-[(3,5-dichloroisonicotinoyI)amino]-3-[2-(2,6-dichiorophenyl)-6-quinolinyl]propanoic acid. Also disclosed is the use of a compound as defined above in the manufacture of medicament for the treatment of alpha4beta7 and/or alpha4beta7 dependent inflammatory or medical conditions (such as asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's diseases and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis) or alpha4 related cancers. |